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Abstract: Prostate cancer (PCa) is the most 
common cancer in American men and its metastatic 
spread is responsible for its high mortality rates. 
Since PCa cells evolve against various treatment 
approaches, there is an urgent need for new 
treatment solutions. Bisphenol A (BPA) is an 
industrial chemical with structural similarities to 
androgens and estrogens and is postulated to 
interfere with androgen receptor (AR) and estrogen 
receptor function by competitive inhibition. 
Previous studies reported that low concentrations of 
BPA stimulate the proliferation of cancer cells 
expressing AR, whereas high concentrations of BPA 
unexpectedly inhibited the growth of those cells. 
This prompted the hypothesis that high 
concentrations of BPA might kill AR-positive, 
treatment-resistant PCa cells. In this study, the 
effect of high concentrations of BPA on AR-positive, 
Enzalutamide (a recent oral AR inhibitor)-resistant 
PCa cells were evaluated. At high concentrations, 
BPA was found to reduce cell growth by 90% and to 
trigger cell death. To explore the underlying 
molecular mechanisms, the expression and activity 
of AR were examined; both were decreased upon 
treatment of high BPA concentrations. In summary, 
high concentrations of BPA can inhibit cell growth 
and stimulate cell death of Enzalutamide-resistant 
PCa by targeting AR signaling. These findings may 
pave the road for novel approaches for treatment-
resistant PCa.   
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I.   INTRODUCTION 
 
Prostate cancer (PCa) is currently both the most prevalent 
and the second deadliest cancer for American men [1]. 
Hormonal therapy and chemotherapy are used to treat 
advanced PCa, but frequently can only palliate the disease. 
Currently, advanced PCa is incurable and there is an urgent 
need to understand PCa development.   
 
Androgens are a group of male hormones vital for normal 
prostate cell growth [2]. The androgens bind to and activate 
the androgen receptor (AR), a transcription factor, in the 
cytoplasm. The resulting androgen-AR complex then 
translocates to the nucleus to bind to DNA and trigger a 
series of AR target gene expression or suppression essential 
for prostate cell growth. Since Huggins and Hodges’ 
breakthrough study proving that PCa cells heavily rely on 
androgens for survival and growth, androgen-deprivation 
therapy (ADT), a hormonal therapy focusing on the 
reduction of androgen levels through chemical or surgical 
means, has served as the standard treatment for advanced 
PCa [3]. The depletion of hormones effectively causes the 
PCa to regress. However, after 1 to 3 years, PCa inevitably 
develops a resistance and progresses into castration-resistant 
PCa (CRPC) [4].   
 
Research has convincingly demonstrated that CRPC has been 
shown to exhibit active AR signaling despite ADT [5]. 
Accordingly, scientists have been exploring a variety 
approaches to more effectively block AR signaling as PCa 
cells develop resistance to treatments. The current frontline 
treatment for advanced PCa is Enzalutamide, an AR 
antagonist that prevents AR binding to DNA, blocks PCa cell 
growth, induces cell death, and shows great promise on 
patients who developed a resistance to earlier generations of 
AR antagonists [6]. However, most men eventually develop 
a resistance to Enzalutamide within 4 to 6 months [7]. 
Therefore, novel approaches are desperately needed in order 
to design novel approaches for treatment-resistant PCa.  
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Bisphenol A (BPA) is an industrial chemical that is widely 
used in everyday products like polycarbonate plastics and 
epoxy resins. BPA has a chemical structure similar to 
estrogen. Previous studies have shown that BPA functions as 
an endocrine disruptor. It binds to and interrupts estrogen 
receptor signaling [8]. Furthermore, BPA has been reported 
to similarly interfere with AR function by competitive 
inhibition of androgen binding [9].  
 
Previous studies reported that while lower concentrations of 
BPA stimulated the proliferation of cancer cells expressing 
AR, higher concentrations of BPA unexpectedly inhibited 
their proliferation [10, 11]. The reason for the differential 
effects of BPA on cancer cell growth is unknown. 
Nevertheless, since BPA may act as an AR antagonist at high 
concentrations, it may continue to interfere with AR activity 
even after enzalutamide resistance develops. Therefore, the 
effects of high concentrations of BPA on the AR signaling in 
advanced PCa and whether BPA can be exploited as a 
treatment option for treatment-resistant PCa are questions 
that warrant further research.  
 
The purpose of this experiment is to determine the effects of 
BPA on viability of enzalutamide-resistant PCa cells. It was 
hypothesized that if enzalutamide-resistant LNCaP prostate 
cells are exposed to higher concentrations of BPA, then cell 
viability will decrease. Cell viability was measured by MTS 
assay and cell death was evaluated by Caspase 3 and poly 
ADP ribose polymerase (PARP) cleavage. To further 
investigate the underlying mechanisms, the expression and 
activity of AR were examined by immunoblotting. The 
control of this study was the group with no BPA treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II. METHODS AND MATERIALS 
 
2.1  Cell Culture and Treatment 
 
Enzalutamide-resistant LNCaP cells were seeded in a 96-
well plate at a density of 5,000 cells per well, with six MTS 
assay trials per group and 9 groups in total. After 24 hours of 
incubation at 37 °C, 9 different concentrations of BPA (0, 2.5, 
5, 10, 20, 40, 80, 160, 320 M; Sigma, St. Louis MO) were 
added to each well. The plate was then incubated for 3 days 
at 37 °C in an incubator, and then subject to MTS assay.   
 
The enzalutamide-resistant LNCaP cells for immunoblotting 
were seeded in 3 100-mm petri dishes at a density of 3 x 106 
cells per dish and incubated at 37 °C in an incubator. After 
24 hours of incubation, 3 different concentrations of BPA (0, 
50, 100 M) were added to each petri dish (1 for each 
concentration). Cells were then incubated for two days at 37 
°C in an incubator, and subject to immunoblotting analysis. 
  
2.2  MTS Assay  
 
To test the anti-proliferative activity of BPA on treatment-
resistant PCa cells, CellTiter 96 Aqueous Non-Radioactive 
Cell Proliferation Assay (MTS) (Promega, Madison WI) was 
performed. Twenty L of MTS/PMS solution was added to 
each well and the cells were incubated for 4 hours. The 
absorbance of each well was read at 490 nm using an 
enzyme-linked immunosorbent assay plate reader (Promega, 
Madison WI) and absorbance of culture medium was 
subtracted from each well containing cells. The average 
absorbance of each group was calculated. Viability was 
calculated by dividing the average absorbance of each 
experimental group by the average absorbance of the control 
group.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3  Immunoblotting  
 
To determine the expression of cleaved Caspase 3 and PARP, 
AR, and cyclin A, immunoblotting was performed with the 
concentrations of BPA that led to moderate and severe 
cytotoxicity. Cells were collected, washed with ice-cold 
phosphate buffered saline (PBS) twice, and then lysed in 
Radio Immuno Precipitation Assay (RIPA) buffer (1% NP-
40, 0.1% SDS, 0.5% Na-DOC, 20 mM HEPES buffer, pH 
7.5, 150 mM NaCl, and 1 tablet of Roche protease inhibitor 
Fig. 1: Structural comparison between estrogen, BPA, and androgen. The hydroxyl groups are a similar distance apart in 
estrogen and BPA, and BPA and androgen are similar on one end.  
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cocktail) for 20 min at 4 °C. The cells were centrifuged in a 
micro centrifuge for 20 minutes at 12,000 rpm and 4 °C. The 
supernatants were aspirated and placed in fresh tubes. Fifty 
g of each cell lysate was mixed with 4 x sodium dodecyl 
sulfate (SDS) loading buffer and loaded to SDS-PAGE gel, 
along with a molecular weight marker. The gel was run for 
1–2 hours at 100V.  
 
The proteins were transferred from the gel to a nitrocellular 
membrane using Mini Trans-Blot cell. The membrane was 
blocked for 1 hour at room temperature using Tris-buffered 
saline (TBST) containing 0.1% Tween 20 and 5% nonfat dry 
milk. The blocking buffer was removed and replaced with 
diluted primary antibodies (anti-cleaved Caspase 3 (Cell 
signaling, Danvers MA), anti-PARP (Cell Signaling, 
Danvers MA), anti-AR (Santa Cruz, Dallas, TX), anti-cyclin 
A (Santa Cruz, Dallas, TX), and anti--actin (Santa Cruz, 
Dallas, TX) in blocking buffer. The membrane was 
incubated with primary antibodies for overnight at 4 °C. The 
membrane was washed with TBST 3 times (5 min each), and 
then incubated with secondary antibody at room temperature 
for 1 hour. The membrane was washed with TBST 3 times (5 
min each). The membrane was covered with transparent 
plastic wrap and the chemiluminescent signal was detected 
using an enhanced chemiluminescence (ECL) detection 
system (Biorad, Hercules, CA) and compared among 
different groups.   
 
III. RESULTS 
 
3.1 Cytotoxic effect of BPA on enzalutamide-resistant 
LNCaP cells 
 
MTS assay was used to evaluate the anti-proliferative 
activity of BPA on enzalutamide resistant LNCaP PCa cells. 
MTS assay is a colorimetric method for accessing cell 
mitochondrial metabolic activity, which indirectly reflects 
viable cell numbers. Catalyzed by NAD(P)H-dependent 
cellular oxidoreductase) existing only in living cells, 3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS), in the presence of 
phenazine methosulfate (PMS), produces a formazan product 
that has an absorbance maximum at 490 nm on PBS. 
Enzalutamide-resistant LNCaP cells were seeded in a 96-
well plate and treated with various concentrations of BPA (0, 
2.5, 5, 10, 20, 40, 80, 160, 320 M) for 3 days. MTS assay 
was then carried out to measure viable cells upon each 
treatment. The absorbance at 490 nm of the control group 
was set as 100% and the other groups were normalized to the 
control group based on their average MTS assay absorbance. 
The results were summarized and presented in Figure 2. The 
data clearly shows an exponential decay trend, with more 
than 90% reduction in relative cell viability for the 160 and 
320 M groups. A linear regression t-test performed on the 
logarithmic relative cell viability at a 0.005 level of 
significance produced a calculated t value of 5.8922 that was 
higher than the table t value of 4.03214, so there is a 
significant difference between the groups. In addition, a high 
r-squared value of 0.8322 indicates a strong negative 
correlation between BPA concentration and cell viability. 
 
MTS assay measures viable cells, but the anti-proliferative 
activity demonstrated by such an assay could result from 
either cytotoxicity (loss of viable cells) or cytostatic activity 
(shift from proliferation to quiescence). Cleavage of Caspase 
3 and PARP is a pre-requisite for cells who undergo final 
stage of cell death and is often used as the apoptotic markers. 
To verify that high concentrations of BPA have cytotoxic 
effects on enzalutamide-resistant LNCaP cells, the cleavage 
of Caspase 3 and PARP in those cells treated with 0, 50, or 
100 M of BPA was analyzed by Western blotting, using 
anti-cleaved Caspase 3 and anti-PARP antibodies. Upon the 
treatment of 100 M of BPA, cleaved Caspase 3 and PARP 
were strongly detected by Western blot (Figure 3), which 
indicates that high concentrations of BPA killed 
enzalutamide-resistant LNCaP cells. 
 
 
Fig. 2: The effect of various concentrations of BPA on the 
relative viability of enzalutamide-resistant LNCaP Cells. 
Enzalutamide-resistant LNCaP Cells were treated with 
different concentrations of BPA for 3 days, and then subject 
to MTS assay as described in “Materials and Methods” 
section. The data are expressed as a percentage of viability 
in relation to the control group. The control group of 0 M 
BPA was set as 100%.  
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Fig. 3: Cleavage of Caspase 3 and PARP was analyzed by 
Western blot in enzalutamide-resistant LNCaP cells treated 
with high concentrations of BPA. Cells were treated with 
BPA (0, 50, or 100 M) for 2 days, and then subject to 
Western blot analysis, using anti-cleaved Caspase 3 and 
anti-PARP antibodies. -actin was used as a loading control. 
 
3.2 Effect of BPA on the expression and activity of AR in 
enzalutamide-resistant LNCaP cells  
 
Next, the mechanism by which high concentrations of BPA 
killed enzalutamide-resistant LNCaP cells was studied. 
Since BPA is an AR antagonist and PCa cells, including 
treatment-resistant PCa cells, rely on AR function for their 
survival and proliferation, the integrity of AR signaling was 
evaluated. The protein level of AR was examined in 
enzalutamide-resistant LNCaP cells treated with 0, 50, 100 
M of BPA by immunoblotting (Figure 4). The protein level 
of Cyclin A was also examined in order to evaluate AR 
activity since its expression is controlled by AR activity. In 
both 50 and 100 M of BPA groups, there is a clear 
reduction in AR and Cyclin A protein levels when compared 
to the control. These results suggest that high concentrations 
of BPA antagonize AR signaling in enzalutamide-resistant 
LNCaP cells. 
 
 
 
Figure 4. The effect of high concentrations of BPA on AR 
signaling in enzalutamide-resistant LNCaP cells. Cells were 
treated with BPA (0, 50, or 100 M) for 2 days, and then 
subject to Western blot analysis, using anti-AR (for AR 
expression) and anti-cyclin A (for AR activity) antibodies. -
actin was used as an internal control for loading. 
 
 
 
 
 
IV. DISCUSSION 
 
The main purpose of this experiment was to determine the 
potential therapeutic effects of BPA on enzalutamide-
resistant PCa. It was hypothesized that high concentrations of 
BPA would decrease the viability of AR-positive, treatment-
resistant PCa cells. The results of the MTS assay show that, 
when compared to the control, all 8 concentrations of BPA 
exhibited a decrease in cell viability, with the 160 and 320 
M groups experiencing a more than 90% decrease in cell 
viability. Caspase 3 and PARP cleavage verified the 
cytotoxic effect of high concentrations of BPA on the 
enzalutamide-resistant LNCaP cells. Furthermore, high 
concentrations of BPA function as an antagonist of AR 
signaling, as indicated by the reduced AR expression and 
activity. These results strongly support the research 
hypothesis.    
 
To determine the relationship between BPA concentration 
and relative cell viability, a linear regression t-test was 
performed and proved that there is a strong negative 
correlation and a statistically significant relationship between 
the two variables. 
 
Other researchers have explored the effects of BPA on the 
AR pathway. Xu’s team identified BPA as an AR antagonist 
[12]. Teng’s group recently studied the binding of BPA and 
its analogues on the androgen receptor and determined that 
BPA is capable of binding to the AR, but not its analogues 
[13]. Interestingly, a recent ISEF winning project reported 
that BPA has differential effect on the growth of AR-positive 
cells; high concentrations of BPA inhibited the growth of 
cancer cells expressing AR whereas low concentrations of 
BPA stimulated the proliferation of those cells [11]. 
However, there has not been any studies linking BPA and the 
AR in enzalutamide-resistant PCa up until this point.  
 
Despite the clinical success of enzalutamide for CRPC 
patients, resistance to enzalutamide eventually develops. 
Several mechanisms of the development of such a resistance 
have been proposed, including mutations in AR that could 
cause structural changes and make the AR unrecognizable to 
enzalutamide. Given the observations that BPA is able to 
bind to the AR and that high concentrations of BPA killed 
enzalutamide-resistant PCa cells and reduced AR expression 
and activity, a possible explanation for the results of this 
experiment is that BPA is capable of binding to the mutated 
AR that is caused by enzalutamide treatment, and thereby 
interferes with AR signaling in enzalutamide-resistant PCa 
cells, which eventually leads to cell death of those treatment-
resistance cells. In future studies, we plan to elucidate the 
molecular action of BPA in enzalutamide-resistant PCa in 
greater detail. The results from this study suggest that BPA is 
a promising candidate for CRPC treatment, and its chemical 
properties can be further analyzed and modified to develop 
-actin 
Cleaved Caspase 3 
Cleaved PARP 
BPA M)   0    50   100 
AR 
-actin 
Cyclin A 
BPA M)   0    50   100 
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and optimize AR antagonists, which may pave the road for 
designing novel approaches for treatment-resistant PCa.  
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